New combo aims to wipe out aggressive breast cancer before surgery
NCT ID NCT07342283
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding the drug QL1706 to standard chemotherapy before surgery can completely eliminate triple-negative breast cancer in 30 patients with stage II or III disease. Participants receive the combination in two phases over about 8 months, then have surgery. The main goal is to see how many have no cancer left at that point.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER (TNBC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Affiliated Hospital of Nantong University
RECRUITINGNantong, Jiangsu, China
Contact Phone: •••-•••-••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Shorter immunotherapy course may be enough for some breast cancer patients — a major trial puts it to the test
- Leftover tumor after breast cancer treatment: a hidden risk revealed
- Experimental pill SHY-ONC6 takes on Hard-to-Treat cancers
- Could a modified protein help immunotherapy fight a tough breast cancer?
- Triple-Drug cocktail aims to tackle Hard-to-Treat cancers
- New hope for Hard-to-Treat breast cancer: drug combo trial launches